183 related articles for article (PubMed ID: 36839960)
1. Liposomal Delivery of MIW815 (ADU-S100) for Potentiated STING Activation.
Ji N; Wang M; Tan C
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839960
[TBL] [Abstract][Full Text] [Related]
2. Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy.
Zheng H; Guo B; Qiu X; Xia Y; Qu Y; Cheng L; Meng F; Zhong Z
Bioact Mater; 2022 Oct; 16():1-11. PubMed ID: 35386324
[TBL] [Abstract][Full Text] [Related]
3. Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4
Luo J; Pang S; Hui Z; Zhao H; Xu S; Yu W; Yang L; Sun Q; Hao X; Wei F; Wang J; Ren X
Theranostics; 2023; 13(14):4836-4857. PubMed ID: 37771774
[No Abstract] [Full Text] [Related]
4. Antagonism of regulatory ISGs enhances the anti-melanoma efficacy of STING agonists.
Filderman JN; Taylor JL; Wang J; Zhang Y; Singh P; Ross MA; Watkins SC; Nedal Al Bzour A; Karapetyan L; Kalinski P; Storkus WJ
Front Immunol; 2024; 15():1334769. PubMed ID: 38312842
[TBL] [Abstract][Full Text] [Related]
5. Discovery of isonucleotidic CDNs as potent STING agonists with immunomodulatory potential.
Dejmek M; Šála M; Brazdova A; Vanekova L; Smola M; Klíma M; Břehová P; Buděšínský M; Dračínský M; Procházková E; Zavřel M; Šimák O; Páv O; Boura E; Birkuš G; Nencka R
Structure; 2022 Aug; 30(8):1146-1156.e11. PubMed ID: 35690061
[TBL] [Abstract][Full Text] [Related]
6. Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potential Immunotherapy for Prostate Cancer.
Esteves AM; Papaevangelou E; Dasgupta P; Galustian C
Front Oncol; 2021; 11():621550. PubMed ID: 33777767
[TBL] [Abstract][Full Text] [Related]
7. Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation.
Gu Z; Hao Y; Schomann T; Ossendorp F; Ten Dijke P; Cruz LJ
J Control Release; 2023 May; 357():531-544. PubMed ID: 37030544
[TBL] [Abstract][Full Text] [Related]
8. Vinylphosphonate-based cyclic dinucleotides enhance STING-mediated cancer immunotherapy.
Dejmek M; Brazdova A; Otava T; Polidarova MP; Klíma M; Smola M; Vavrina Z; Buděšínský M; Dračínský M; Liboska R; Boura E; Birkuš G; Nencka R
Eur J Med Chem; 2023 Nov; 259():115685. PubMed ID: 37567057
[TBL] [Abstract][Full Text] [Related]
9. Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas.
Meric-Bernstam F; Sweis RF; Hodi FS; Messersmith WA; Andtbacka RHI; Ingham M; Lewis N; Chen X; Pelletier M; Chen X; Wu J; McWhirter SM; Müller T; Nair N; Luke JJ
Clin Cancer Res; 2022 Feb; 28(4):677-688. PubMed ID: 34716197
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-cell mediated anti-tumor immunity in an esophageal adenocarcinoma model.
Zaidi AH; Kelly RJ; Gorbunova A; Omstead AN; Salvitti MS; Zheng P; Kosovec JE; Lee S; Ayazi S; Babar L; Finley GG; Goel A; Jobe BA
Oncotarget; 2021 Feb; 12(4):292-303. PubMed ID: 33659041
[TBL] [Abstract][Full Text] [Related]
11. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer.
Lee SJ; Yang H; Kim WR; Lee YS; Lee WS; Kong SJ; Lee HJ; Kim JH; Cheon J; Kang B; Chon HJ; Kim C
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145029
[TBL] [Abstract][Full Text] [Related]
12. Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study.
Meric-Bernstam F; Sweis RF; Kasper S; Hamid O; Bhatia S; Dummer R; Stradella A; Long GV; Spreafico A; Shimizu T; Steeghs N; Luke JJ; McWhirter SM; Müller T; Nair N; Lewis N; Chen X; Bean A; Kattenhorn L; Pelletier M; Sandhu S
Clin Cancer Res; 2023 Jan; 29(1):110-121. PubMed ID: 36282874
[TBL] [Abstract][Full Text] [Related]
13. 2',4'-LNA-Functionalized 5'-S-phosphorothioester CDNs as STING agonist.
Yeboah SK; Zigli A; Sintim HO
Chembiochem; 2024 May; ():e202400321. PubMed ID: 38720428
[TBL] [Abstract][Full Text] [Related]
14. Photodynamic immunotherapy using ADU-S100-modified nanoparticles to treat triple-negative breast cancer.
Ge T; Ge W; Zhang L; Yu G; Li Y; Sun L; Dong F; Yao Z; Shi L; Wang Y
Nanomedicine (Lond); 2023 Apr; 18(9):755-767. PubMed ID: 37306248
[No Abstract] [Full Text] [Related]
15. Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy.
Koshy ST; Cheung AS; Gu L; Graveline AR; Mooney DJ
Adv Biosyst; 2017 Feb; 1(1-2):. PubMed ID: 30258983
[TBL] [Abstract][Full Text] [Related]
16. Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy.
Motedayen Aval L; Pease JE; Sharma R; Pinato DJ
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33081170
[TBL] [Abstract][Full Text] [Related]
17. Supramolecular Cyclic Dinucleotide Nanoparticles for STING-Mediated Cancer Immunotherapy.
Xu L; Deng H; Wu L; Wang D; Shi L; Qian Q; Huang X; Zhu L; Gao X; Yang J; Su Y; Feng J; Zhu X
ACS Nano; 2023 Jun; 17(11):10090-10103. PubMed ID: 37253192
[TBL] [Abstract][Full Text] [Related]
18. Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models.
Papaevangelou E; Esteves AM; Dasgupta P; Galustian C
Front Immunol; 2023; 14():1196829. PubMed ID: 37465665
[TBL] [Abstract][Full Text] [Related]
19. Selective STING stimulation in dendritic cells primes antitumor T cell responses.
Jneid B; Bochnakian A; Hoffmann C; Delisle F; Djacoto E; Sirven P; Denizeau J; Sedlik C; Gerber-Ferder Y; Fiore F; Akyol R; Brousse C; Kramer R; Walters I; Carlioz S; Salmon H; Malissen B; Dalod M; Piaggio E; Manel N
Sci Immunol; 2023 Jan; 8(79):eabn6612. PubMed ID: 36638189
[TBL] [Abstract][Full Text] [Related]
20. Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy.
Wu JJ; Zhao L; Hu HG; Li WH; Li YM
Med Res Rev; 2020 May; 40(3):1117-1141. PubMed ID: 31793026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
